Core Insights - Abbott Laboratories (NYSE:ABT) is a prominent global healthcare company recognized for its innovative medical devices, diagnostics, and nutritional products, competing with major players like Johnson & Johnson and Medtronic [1][5] - Evercore ISI has set a price target of $144 for Abbott, indicating a potential increase of approximately 16.16% from its current trading price of $123.97 [1][5] Product Innovation - The recent launch of the Libre Assist feature within Abbott's Libre app at CES 2026 utilizes artificial intelligence to assist individuals with diabetes in making informed food choices, predicting glucose level impacts from various foods [2][5] - This innovation is expected to enhance Abbott's market position and potentially drive stock growth [2][5] Stock Performance - The current stock price of ABT is $124.26, reflecting a slight increase of 0.05% or $0.07, with trading occurring between $122.50 and $124.30 on the day [3][5] - Over the past year, ABT has experienced a high of $141.23 and a low of $110.86, indicating volatility and growth potential [3][5] Market Capitalization - Abbott's market capitalization is approximately $216.27 billion, showcasing its significant presence in the healthcare sector [4][5] - The stock has a trading volume of 1,473,285 shares, indicating active trading and interest from investors [4]

For people living with diabetes, daily health decisions are constant, and food choices are among the most critical, especially for those managing their condition solely through lifestyle changes. The challenge is intensified by each person's unique response to food, making every meal decision complex. 11235 "The Libre Assist feature is a gamechanger for me," said Shirley Bovshow, who lives with Type 2 diabetes and is one of the first to try Abbott's new feature. "Traditional food logging apps left me guessi ...